Despite Phase 3 Failure, Sarepta Still Sees Path for Muscle Disease Drugs to Secure Full FDA Approval
Sarepta Therapeutics attributed the Phase 3 failure to the Covid-19 pandemic, during which many patients…
Despite Phase 3 Failure, Sarepta Still Sees Path for Muscle Disease Drugs to Secure Full FDA Approval
Sarepta Therapeutics attributed the Phase 3 failure to the Covid-19 pandemic, during which many patients missed multiple doses of its Duchenne muscular dystrophy therapies. The company plans to discuss with the FDA traditional regulatory approvals based on the totality of data that includes real world evidence from the years these drugs have been commercially available…
Medtronic Exec: AI Is Improving Device Launches & Patient Outcomes
Jennifer Thompson, Medtronic’s vice president of U.S. aortic sales, detailed how AI is transforming medical device commercialization during a fireside chat at Reuters’ MedTech conference. The technology is helping teams identify patients, optimize their sales deployment and discover care bottlenecks. The post Medtronic Exec: AI Is Improving Device Launches & Patient Outcomes appeared first on…
Louisiana tardó meses en alertar a la población tras la muerte de dos bebés durante un brote de tos ferina
Cuando hay un brote de una enfermedad prevenible con vacunas, los funcionarios estatales de salud pública habitualmente toman ciertas medidas para alertar a los residentes y difundir actualizaciones sobre la amenaza creciente. Esa es la práctica estándar, según expertos en salud pública y enfermedades infecciosas consultados por KFF Health News y NPR. El objetivo es…
ISPOR Europe: “EU Pharmaceutical Package: Where Are We and Where Are We Going?”
That is the title of my Fast Facts presentation at ISPOR Europe at 11:30 GMT on Tuesday, November 11 with Tiago Beck. If you’re in Glasgow next week, feel free to stop by this session. Should be interesting. The abstract is below. As trilogue negotiations on the EU pharmaceutical package progress, stakeholders across the healthcare…
Qué pueden hacer los consumidores frente al caos del Obamacare
Este año, el período de inscripción abierta para adquirir un plan médico en los mercados estatales y federales establecidos por la Ley de Cuidado de Salud a Bajo Precio (ACA, conocida también como Obamacare), que comenzó el 1 de noviembre en la mayoría de los estados, está lleno de incertidumbre y confusión para más de…
Therapy 2.0: An AI-Powered Science of Language Intervention
By safety and cautiously integrating LLMs in a clinician setting, we have the potential for the ultimate levels of personalization: the perfect words for the right person at the right time. The post Therapy 2.0: An AI-Powered Science of Language Intervention appeared first on MedCity News.
The Critical Role Payers Can Play in Closing the Oral Health Gap
Salivary testing represents more than a new tool; it’s a scalable strategy to shift care upstream, reduce preventable emergencies, and bring equity to a population too often left behind. The post The Critical Role Payers Can Play in Closing the Oral Health Gap appeared first on MedCity News.
Congressional Stalemate Creates Chaos for Obamacare Shoppers
This year’s Obamacare open enrollment period, which started Nov. 1 in most states, is full of uncertainty and confusion for the more than 24 million people who buy health insurance through the federal and state Affordable Care Act marketplaces. Even with sign-up season underway, the fate of the enhanced premium tax credits that make coverage…
Louisiana Took Months To Sound Alarm After Two Babies Died in Whooping Cough Outbreak
When there’s an outbreak of a vaccine-preventable disease, state health officials typically take certain steps to alert residents and issue public updates about the growing threat. That’s standard practice, public health and infectious disease experts told KFF Health News and NPR. The goal is to keep as many other vulnerable people as possible from getting…
The ‘After Phase’ Is Missing: Why Every GLP-1 Prescription Needs an Exit
By HOLLI BRADISH-LANE I’ve seen clients start GLP-1 medications full of hope—and stop them feeling betrayed by their own biology. Some reached their limit with side effects: relentless nausea, fatigue, or the quiet loss of joy in eating. Others simply couldn’t afford to stay on. A few never saw the promised results at all. But…
